ArticleFrontiers in allergy2026
Cpg boosts peptide-based oral immunotherapy in mice with peanut allergy.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Effective therapies for peanut allergy (PA) remain limited. Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) have emerged as promising adjuvants for allergen-specific immunotherapy (AIT). This study aimed to evaluate whether a liposomal delivery system co-encapsulating peanut extract and CpG enhances therapeutic efficacy in a murine PA model and to elucidate the underlying immunoregulatory mechanisms. Methods: A murine PA model was established using peanut extract. Liposomes were formulated to carry peanut extract alone (LipP), CpG alone (LipC), both (LipCP), or were empty (LipE). PA mice received daily gavage of these formulations for two weeks. Clinical symptoms, antibody profiles, intestinal mediator release, and regulatory immune cell populations were assessed. Results: PA mice exhibited severe anaphylaxis, including a 6.0-fold increase in diarrhea incidence (Cohen's d = 8.21, 95% CI: 5.14-11.28) and a 2.3 °C median core temperature decrease (Cohen's d = 7.94, 95% CI: 4.89-10.99) compared to naive controls (NC). LipCP treatment substantially reduced PA severity: diarrhea incidence decreased by 89% (Cohen's d = 7.86, 95% CI: 4.78-10.94), core temperature reduction was abolished, serum IgE decreased by 78% (Cohen's d = 6.58, 95% CI: 3.85-9.31), and IgG2a/IgG2c levels were restored. LipCP also suppressed intestinal mast cell and eosinophil activation and increased intestinal B10 cell frequency by 3.1-fold (Cohen's d = 6.27, 95% CI: 3.64-8.90) and Tr1 cell frequency by 4.2-fold (Cohen's d = 7.15, 95% CI: 4.21-10.09). In contrast, LipP, LipC, or LipE showed only modest, non-significant effects. Conclusions: Liposomal co-delivery of peanut extract and CpG effectively suppresses peanut allergy in mice by restoring B10 cell and Tr1 cell-mediated immune tolerance. This approach warrants further investigation for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.